Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 858 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IV Lung Non-Small Cell Cancer AJCC v7 Clear all
Terminated Phase 3 Interventional

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00551733
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, paclitaxel poliglumex
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
41
States / cities
Scottsdale, Arizona • Burbank, California • Escondido, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

NCT01839955
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, quinacrine dihydrochloride - Escalation dose, laboratory biomarker analysis, pharmacological study, quinacrine dihydrochloride - Extension dose
Drug · Other
Lead sponsor
Neelesh Sharma MD PhD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

TG4010 and Nivolumab in Patients With Lung Cancer

NCT02823990
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
TG4010, Nivolumab
Biological
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Duarte, California • Sacramento, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

NCT00986297
View directory record Official record
Conditions
Lung Cancer
Interventions
hypofractionated radiation therapy
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Stanford, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 10, 2026, 6:56 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer

NCT00354562
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
ABT-751, Placebo, Docetaxel
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Burbank, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

NCT00050960
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
bexarotene with carboplatin and paclitaxel, carboplatin and paclitaxel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
121
States / cities
Montgomery, Alabama • Tucson, Arizona • Concord, California + 102 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

NCT01281124
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Azacitidine, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

NCT06517433
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Interventions
upifitamab rilsodotin
Drug
Lead sponsor
Mersana Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 10, 2026, 6:56 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00005825
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, mitomycin C, tretinoin, vinorelbine tartrate
Drug
Lead sponsor
Raghu Nandan, M.D., Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
ABT-869 .25 mg/kg, ABT-869 0.10 mg/kg
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers

NCT01729689
View directory record Official record
Conditions
Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
counseling intervention, questionnaire administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00407550
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine HCL, pemetrexed disodium
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00408460
View directory record Official record
Conditions
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
imatinib mesylate, paclitaxel
Drug
Lead sponsor
University of Washington
Other
Eligibility
70 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Albuquerque, New Mexico • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 10, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional Results available

Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00280748
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
pemetrexed disodium, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 10, 2026, 6:56 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional Results available

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340
View directory record Official record
Conditions
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Osimertinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Athens, Georgia • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT00431015
View directory record Official record
Conditions
Lung Cancer
Interventions
IPI-504
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

NCT00047840
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Interventions
ZD6474, Placebo, Docetaxel
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 1 Interventional

Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00857025
View directory record Official record
Conditions
Lung Cancer
Interventions
beta-glucan MM-10-001, flow cytometry, laboratory biomarker analysis, questionnaire administration
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 10, 2026, 6:56 AM EDT
Completed Phase 2 Interventional

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

NCT00062062
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gefitinib, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
140
States / cities
Scottsdale, Arizona • Fort Collins, Colorado • Jacksonville, Florida + 88 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 10, 2026, 6:56 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC

NCT05691829
View directory record Official record
Conditions
NSCLC Stage IV
Interventions
Pembrolizumab, Radiation, Chemotherapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 10, 2026, 6:56 AM EDT
Terminated Phase 1 Interventional

RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT01193881
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Oct 10, 2026, 6:56 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions
Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Newport Beach, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 10, 2026, 6:56 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 10, 2026, 6:56 AM EDT